You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 10,918,616

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,918,616

Title:	Fumarate ester pharmaceutical compositions
Abstract:	Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.
Inventor(s):	Dyakonov; Tatyana (Greensboro, NC), Agnihotri; Sunil (Scarborough, ME), Fatmi; Aqeel A. (High Point, NC)
Assignee:	BANNER LIFE SCIENCES LLC (High Point, NC)
Application Number:	16/129,904
Patent Claims:	1. A method of treating or reducing symptoms of a multiple sclerosis or psoriasis in a subject, the method comprising administering an oral pharmaceutical composition comprising an immediate releasing single phase non-aqueous liquid vehicle comprising a suspension of a fumarate ester or a salt thereof having the formula: ##STR00004## wherein R.sub.1 and R.sub.2, may be the same or different, and independently represent hydrogen or methyl. 2. The composition of claim 1, wherein R.sub.1 is hydrogen. 3. The composition of claim 1, wherein R.sub.1 is methyl. 4. The composition of claim 1, wherein R.sub.2 is methyl. 5. The composition of claim 1, wherein R.sub.1 is hydrogen and R.sub.2 is methyl. 6. The composition of claim 1, wherein R.sub.1 is methyl and R.sub.2 is methyl. 7. The method of claim 1, wherein the fumarate ester is: ##STR00005## or a salt thereof. 8. The method of claim 1, wherein the fumarate ester is: ##STR00006## 9. The method of claim 1, wherein the composition comprises about 60 mg to about 200 mg of the fumarate ester or salt thereof. 10. The method of claim 1, wherein the composition comprises about 90 mg to about 100 mg or about 100 mg to about 200 mg of the fumarate ester or salt thereof. 11. The method of claim 1, wherein the liquid vehicle comprises mono- and di-glycerides, polyvinylpyrrolidone, and polyoxyl 40 hydrogenated castor oil. 12. The method of claim 1, wherein the composition comprises: about 30% to about 40% of the fumarate ester or salt thereof by weight of the composition; and about 55% to about 65% of the liquid vehicle by weight of the composition. 13. The method of claim 1, wherein the liquid vehicle comprises about 5% of lactic acid by weight of the composition. 14. The method of claim 1, wherein the composition is encapsulated in a capsule. 15. The method of claim 14, wherein the capsule provides delayed release of the fumarate ester or salt thereof. 16. The method of claim 1, wherein upon administration to a subject, the composition activates a nuclear factor erythroid-derived 2-like (Nrf2) dependent pathway.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.